Oral small-molecule "molecular glue" degrader · relapsed/refractory multiple myeloma Phase I/IIa clinical trial
Official protocol title:A Multicenter, Non-Randomized, Open-Label Phase I/IIa Clinical Study Evaluating the Safety, Tolerability, and Efficacy of ICP-490 Monotherapy and in Combination with Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Trial Summary
This is a Phase I/IIa clinical trial sponsored by InnoCare Pharma (Beijing) Co., Ltd., primarily targeting patients with relapsed and/or refractory multiple myeloma (r/r MM). The treatment regimen employs an innovative chemical drug (ICP-490) as monotherapy or in combination with a glucocorticoid (dexamethasone), administered cyclically in 28-day cycles. The trial is conducted at a total of 6 top domestic hospitals in China, including Peking University People's Hospital, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Zhejiang University School of Medicine, Shengjing Hospital of China Medical University, and Henan Cancer Hospital. This study is a domestic multicenter clinical trial, with no international medical centers participating at present.
Participating Centers1 in China + 5 overseas
Source and Verification
Every fact on this page is derived from the official study protocol document below. The source document is archived as a PDF for direct verification.
- Document type
- CDE clinical trial registration filing (original PDF)
- Official registration number
- CTR20223160
- Verify on the NMPA CDE public platformby entering CTR20223160 in the registration-number field. The platform is a search interface with no permanent per-study URL, so a direct link is not possible.
- Last reconciled
- 2026-09-07
Frequently Asked Questions about this Study
Structured facts derived from official protocol filings for patient and family reference
According to official protocol filings (target population synthesized by CMDN from study details, not an official CDE field), this study is primarily designed for patients with [Relapsed/refractory]. Eligibility requires verified clinical confirmation by investigators regarding prior lines of therapy, active disease biomarkers, and performance status.
According to verified protocol filings, key eligibility thresholds include: age ≥ 18 years, ECOG performance status ≤ 2. The study specifies 9 inclusion and 11 exclusion criteria covering detailed organ function and medical history. Final enrollment confirmation is determined by investigators at participating hospital trial centers.
The core therapeutic target or investigational mechanism is [Oral small-molecule "molecular glue" degrader]. It aims to selectively eradicate clonal plasma cells or redirect anti-tumor immune responses, representing an active area of precision hematology research.
This study is registered as a [Phase I/IIa] clinical trial. The protocol is conducted under rigorous ethical and Good Clinical Practice (GCP) oversight approved by institutional ethics committees.
This is an international multi-centre study with 1 study centres in China and 5 overseas centres. The lead institution is [Peking University People's Hospital]. Prominent sites include Peking University People's Hospital, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shengjing Hospital of China Medical University, among others. Eligible domestic patients can seek screening at the nearest participating centre.
The official public registration identifier for this protocol is [CTR20223160] (CDE_CTR). Patients and researchers can verify registration details and regulatory authorizations directly on the official NMPA CDE platform.
Key Information
Status
Recruiting
Phase
Phase I/IIa
Target / Therapy
Oral small-molecule "molecular glue" degrader
Sponsor
InnoCare Pharma (Beijing) Co., Ltd.
Principal Investigator
Xiaojun Huang
Lead Institution
Peking University People's Hospital
Participating Centers
1 in China + 5 overseas
CDE Registry ID
CTR20223160
ClinicalTrials.gov ID
NCT05719701Trial information is translated from the Chinese source record and reviewed by CMDN. Confirm current status and eligibility with the study team.
Where this study sits in the landscape
Browse comparable active studies by disease stage, modality and province
Keywords
Considering a non-trial option?
International participation must be confirmed directly with the study team. If a clinical trial is not practical, review our independent guide to CAR-T in China.
View CAR-T in China Guide →Evidence · Process · Costs · Verified hospitals
Protocol drugs and related tests are fully covered by the sponsor. All studies are strictly supervised by ethics committees, and patients retain the legal right to withdraw at any time.
Read application guide & patient rights